PreludeDx™ Presents New DCISionRT® Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling...

Related Keywords

Mccormick Place ,Illinois ,United States ,Chicago ,American ,Pat Whitworth ,Dan Forche ,Andrew Wade ,Cory Dunn ,Instagram ,Linkedin ,Prnewswire Prelude Corporation Preludedx ,National Cancer Institute ,American Society Of Clinical Oncology ,Nashville Breast Center ,University Of Tennessee ,Prelude Corporation ,Facebook ,University Of California San Francisco ,American Society ,Clinical Oncology ,Annual Meeting ,Breast Surgical Oncologist Director ,Associate Professor ,Managing Partner ,California San Francisco ,Know Your Risk ,Fjord Ventures ,Decision Score ,Preludedx ,